Tarsus Pharmaceuticals, Inc. TARS Offering costs included within accounts payable and other accrued liabilities
Offering costs included within accounts payable and other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s offering costs included within accounts payable and other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s offering costs included within accounts payable and other accrued liabilities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported offering costs included within accounts payable and other accrued liabilities of $0 in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s offering costs included within accounts payable and other accrued liabilities changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s offering costs included within accounts payable and other accrued liabilities decreased by 100.0% year-over-year, from $354K to $0.
- What does offering costs included within accounts payable and other accrued liabilities mean?
- This represents costs associated with equity or debt offerings that have been incurred but remain unpaid at the end of the reporting period. These costs are typically deferred and subsequently offset against the proceeds of the offering. Monitoring this provides insight into the timing and magnitude of capital raising activities.